SEATTLE, June 28 /PRNewswire/ -- Immunex Corporation (Nasdaq: IMNX)
announced today that Barry G. Pea will succeed Scott G. Hallquist as the
company's senior vice president, general counsel and secretary. In his new
role, Mr. Pea will become an executive officer of Immunex. Mr. Hallquist will
focus his efforts on the company's alliance management initiatives, including
potential product and technology acquisitions.
"Barry's appointment reflects the strength of the company's succession
planning efforts," said Ed Fritzky, Immunex chairman and CEO. "Expanding his
already strong leadership role in the company will facilitate a strategic
transition full of opportunity.
"Scott has helped Immunex navigate many business challenges and develop a
top biotechnology law department. We are also fortunate to be able to apply
Scott's energies in the further external development of the company."
Mr. Pea, 42, joined Immunex in 1996 as associate general counsel and was
appointed vice president and deputy general counsel in 1998. His 14 years of
legal experience include 11 years in the pharmaceutical industry. Prior to
joining Immunex, Mr. Pea was senior counsel for Glaxo Wellcome Inc. He
received a J.D. with honors from Duke University School of Law in 1986 and a
B.A. with high honors from Wheaton College in 1980.
Mr. Hallquist, 46, has been general counsel of Immunex since 1989, and
will now direct his efforts to alliance development as executive advisor. He
will lead the alliance team's efforts to acquire products and technologies to
enhance the company's research platforms and provide new product candidates to
expand the company's market positions in cancer, autoimmune and inflammatory
disorders. He holds M.B.A. and J.D. degrees from the University of
North Carolina, and a B.S. from Duke University.
The changes are effective immediately.
Immunex Corporation is a biopharmaceutical company dedicated to improving
lives through immune system science innovations.
American Home Products Corporation owns a majority interest in Immunex.
AHP is one of the world's largest research-based pharmaceutical and health
care products companies. It is a leader in the discovery, development,
manufacturing and marketing of prescription drugs, including biotechnological
and vaccine products, animal health care products and over-the-counter
medications.
NOTE: This news release contains forward-looking statements that involve
risks and uncertainties, including risks associated with clinical development,
regulatory approvals, product commercialization and other risks described from
time to time in the SEC reports filed by Immunex, including the most recently
filed Form 10-Q and Form 10-K. An electronic version of this news release
-- as well as additional information about Immunex of interest to investors,
customers, future employees and patients -- is available on the Immunex home
page at http://www.immunex.com.
SOURCE Immunex Corporation
 back to top
Related links:
http://www.immunex.com
Company News On-Call:
http://www.prnewswire.com/comp/434644.html or fax,
800-758-5804, ext. 434644
CONTACT:
Media, Tim Warner, 206-470-4193, or
Investors, Mark Leahy, 206-389-4363, both of Immunex Corporation
|
